CRISPR-Edited Mice Help Reveal Potential Nanoparticle Treatment for ACDMPV
Research By: Vladimir Kalinichenko, MD, PhD
Post Date: August 12, 2019 | Publish Date: June 14, 2019
Alveolar Capillary Dysplasia with Misalignment of Pulmonary Veins (ACDMPV) is a very rare congenital respiratory disorder that usually proves fatal to infants within a month of birth.
But new findings from researchers at Cincinnati Children’s suggest a potential step forward toward longer survival.
Scientists here used CRISPR/Cas9 to generate mice that faithfully mimic the disorder. The new mouse model allowed researchers to pinpoint the disorder’s cause and identify a potential nanoparticle-based treatment.
Findings appear in the American Journal of Respiratory and Critical Care Medicine.
|Original title:||The S52F FOXF1 Mutation Inhibits STAT3 Signaling and Causes Alveolar Capillary Dysplasia|
|Published in:||American Journal of Respiratory and Critical Care Medicine|
|Publish date:||June 14, 2019|